Transcatheter Heart Valve Market size was valued at USD 6.33 billion in 2021, growing at a CAGR of 15% from 2023-28. Transcatheter heart valves (THV) are used to replace the heart valves with a prosthetic valve for treatment of severe aortic stenosis and mitral regurgitation. These heart valve diseases can be congenital or acquired later in life due to age related life style changes and may be other underlying diseases. If these are not treated can cause heart failure, stroke, blood clots, or death due to sudden cardiac arrest. Aortic stenosis is a condition when the aortic valve does not fully open, causing blood flow to be restricted. These high-risk patients are those who are ineligible for surgical aortic valve replacement (SAVR) and cannot be operated on. Transcatheter aortic valve replacement (TAVR) includes implanting new aortic valves to restore the aortic valve’s capacity to circulate blood. Aortic stenosis is becoming more common, which has led to an increase in the requirement for transcatheter aortic valve implantation.